Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP514363.RAcxWXGkJUdFo3R8sVq29bp5alWDKmpKyi0lRlTkRocnU130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP514363.RAcxWXGkJUdFo3R8sVq29bp5alWDKmpKyi0lRlTkRocnU130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP514363.RAcxWXGkJUdFo3R8sVq29bp5alWDKmpKyi0lRlTkRocnU130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP514363.RAcxWXGkJUdFo3R8sVq29bp5alWDKmpKyi0lRlTkRocnU130_provenance.
- NP514363.RAcxWXGkJUdFo3R8sVq29bp5alWDKmpKyi0lRlTkRocnU130_assertion description "[The putative interferon (IFN) response elements IRF-1/2 and ISGF3 are present in the promoter of the CD317 gene, and IFN has been used for the treatment of not only myeloproliferative diseases but also solid tumors such as renal cell carcinoma (RCC) and melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP514363.RAcxWXGkJUdFo3R8sVq29bp5alWDKmpKyi0lRlTkRocnU130_provenance.
- NP514363.RAcxWXGkJUdFo3R8sVq29bp5alWDKmpKyi0lRlTkRocnU130_assertion evidence source_evidence_literature NP514363.RAcxWXGkJUdFo3R8sVq29bp5alWDKmpKyi0lRlTkRocnU130_provenance.
- NP514363.RAcxWXGkJUdFo3R8sVq29bp5alWDKmpKyi0lRlTkRocnU130_assertion SIO_000772 19032371 NP514363.RAcxWXGkJUdFo3R8sVq29bp5alWDKmpKyi0lRlTkRocnU130_provenance.
- NP514363.RAcxWXGkJUdFo3R8sVq29bp5alWDKmpKyi0lRlTkRocnU130_assertion wasDerivedFrom befree-20150227 NP514363.RAcxWXGkJUdFo3R8sVq29bp5alWDKmpKyi0lRlTkRocnU130_provenance.
- NP514363.RAcxWXGkJUdFo3R8sVq29bp5alWDKmpKyi0lRlTkRocnU130_assertion wasGeneratedBy ECO_0000203 NP514363.RAcxWXGkJUdFo3R8sVq29bp5alWDKmpKyi0lRlTkRocnU130_provenance.
- befree-20150227 importedOn "2015-02-27" NP514363.RAcxWXGkJUdFo3R8sVq29bp5alWDKmpKyi0lRlTkRocnU130_provenance.